Show simple item record

dc.contributor.authorPineda Martos, Carmen María
dc.contributor.authorAguilera Tejero, Escolástico
dc.contributor.authorMorales, María C.
dc.contributor.authorBelinchón-Lorenzo, Silvia
dc.contributor.authorGómez-Nieto, Luis C.
dc.contributor.authorGarcía, Pablo
dc.contributor.authorMartínez-Moreno, Julio M.
dc.contributor.authorRodríguez-Ortiz, Maria E.
dc.contributor.authorLópez, Ignacio
dc.date.accessioned2018-12-07T11:01:54Z
dc.date.available2018-12-07T11:01:54Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/10396/17558
dc.description.abstractTreatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin in dogs with leishmaniasis and decreased renal function, 28 dogs suffering from leishmaniasis and chronic kidney disease (CKD) were treated with oral marbofloxacin at 2 mg/Kg/day for 28 days. During treatment dogs were assessed by performing weekly physical exams, measuring blood pressure and evaluating blood and urine parameters. Lymph node aspirations were also obtained at days 0 and 28. The global clinical score decreased significantly, from 6.2±3.4 to 4.7±3.1 (p = 0.0001), after treatment. Marbofloxacin also decreased parasitic load in 72% of the dogs. No significant differences in plasma creatinine, urine specific gravity, urinary concentrations of cystatin C, ferritin and urinary protein loss were detected during treatment. A transient but significant decrease in blood pressure was detected up to day 14 (from 180.1±36.6 to 166.0±32.7 mmHg; p = 0.016). Moreover, dogs showed a significant increase in plasma albumin concentration (from 15.0±5.2 to 16.6±3.9 g/L; p = 0.014) and a significant decrease in globulin concentration (from 59.0±18.1 to 54.1±18.0 g/L; p = 0.005). The results demonstrate that, in addition to being effective for treatment of CanL, marbofloxacin is a very safe drug in dogs with CKD and leishmaniasis.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Sciencees_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourcePLoS ONE 12(10): e0185981 (2017)es_ES
dc.subjectCanine leishmaniasises_ES
dc.subjectCanLes_ES
dc.titleTreatment of canine leishmaniasis with marbofloxacin in dogs with renal diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0185981es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record